Balaji Gandhi Sells 4,687 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 4,687 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $76,679.32. Following the transaction, the chief financial officer directly owned 150,569 shares in the company, valued at approximately $2,463,308.84. This represents a 3.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Thursday, January 15th, Balaji Gandhi sold 975 shares of Phreesia stock. The stock was sold at an average price of $16.38, for a total value of $15,970.50.
• On Thursday, January 8th, Balaji Gandhi sold 8,009 shares of Phreesia stock. The shares were sold at an average price of $17.01, for a total transaction of $136,233.09.

Phreesia Trading Down 3.8%

Shares of PHR traded down $0.63 during midday trading on Tuesday, hitting $15.76. The stock had a trading volume of 888,246 shares, compared to its average volume of 1,011,187. The stock’s 50 day moving average is $18.24 and its 200 day moving average is $23.18. The firm has a market cap of $950.23 million, a PE ratio of -157.59 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. Phreesia, Inc. has a 1 year low of $15.41 and a 1 year high of $32.76.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The firm had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. During the same period in the previous year, the company earned ($0.25) EPS. The firm’s revenue for the quarter was up 12.7% compared to the same quarter last year. As a group, analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Large investors have recently bought and sold shares of the business. Moody National Bank Trust Division lifted its holdings in Phreesia by 63.8% during the fourth quarter. Moody National Bank Trust Division now owns 195,944 shares of the company’s stock worth $3,315,000 after buying an additional 76,345 shares during the period. SG Americas Securities LLC purchased a new position in shares of Phreesia in the 4th quarter valued at $1,203,000. Diversified Trust Co. raised its position in shares of Phreesia by 12.2% in the 4th quarter. Diversified Trust Co. now owns 51,422 shares of the company’s stock worth $870,000 after acquiring an additional 5,600 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Phreesia during the 3rd quarter worth $4,173,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Phreesia during the 3rd quarter worth $183,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PHR. Canaccord Genuity Group decreased their price target on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, December 9th. JPMorgan Chase & Co. reduced their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 9th. Royal Bank Of Canada started coverage on shares of Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price for the company. Barclays decreased their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, December 16th. Finally, Mizuho dropped their target price on shares of Phreesia from $36.00 to $28.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 10th. Seventeen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.